Reviewing Mangoceuticals (NASDAQ:MGRX) and Lipocine (NASDAQ:LPCN)

Mangoceuticals (NASDAQ:MGRX) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Risk and Volatility

Mangoceuticals has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Mangoceuticals and Lipocine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mangoceuticals	-4,536.70%	-109.38%	-102.40%
Lipocine	-487.00%	-59.30%	-53.37%

Institutional & Insider Ownership

56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Mangoceuticals and Lipocine”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mangoceuticals	$460,000.00	12.23	-$20.64 million	($2.56)	-0.13
Lipocine	$1.98 million	9.29	-$9.63 million	($1.69)	-1.36

Lipocine has higher revenue and earnings than Mangoceuticals. Lipocine is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Mangoceuticals and Lipocine, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mangoceuticals	1	0	0	0	1.00
Lipocine	1	1	0	1	2.33

Lipocine has a consensus target price of $15.00, suggesting a potential upside of 555.02%. Given Lipocine’s stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Mangoceuticals.

Summary

Lipocine beats Mangoceuticals on 9 of the 14 factors compared between the two stocks.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.

About Lipocine

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.